• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CAPECITABINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CAPECITABINE chembl:CHEMBL1773 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    XELODA
    RO-09-1978000
    CAPECITABINE
    RO-091978000
    XELODA®
    CAPECITABINA
    CAPECITABINUM
    RO-09-1978-000
    PENTYL 1-(5-DEOXY-BETA-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINECARBAMATE
    (1-(5-DEOXY-BETA-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINYL)-CARBAMIC ACID PENTYL ESTER
    PENTYL [1-(5-DEOXY-BETA-D-RIBOFURANOSYL)-5-FLUORO-2-OXO-1,2-DIHYDROPYRIMIDIN-4-YL]CARBAMATE
    PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
    CAPECITABIN
    chemidplus:154361-50-9
    drugbank:01101
    chembl:CHEMBL1773
    pubchem.compound:60953
    rxcui:194000

    Drug Info:

    (6 More Sources)

    Publications:

    Sharon E et al., 2010, Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine., Head Neck Oncol
    von Minckwitz et al., 2009, Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study., J. Clin. Oncol.
    Geyer et al., 2006, Lapatinib plus capecitabine for HER2-positive advanced breast cancer., N. Engl. J. Med.
    Grellety et al., 2016, A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy., Ann. Oncol.
    Bartsch et al., 2007, Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer., J. Clin. Oncol.
    Baselga et al., 2016, Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer., Clin. Cancer Res.
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Saura et al., 2014, Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer., J. Clin. Oncol.
    Pellicer M et al., 2017, Identification of new SNPs associated with severe toxicity to capecitabine., Pharmacol Res
    Stepanova et al., 2005, [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]., Vopr Onkol
    Caudle et al., 2013, Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing., Clin. Pharmacol. Ther.
    Fischel et al., 2006, Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine., Anticancer Drugs
    Carlini et al., 2005, UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan., Clin. Cancer Res.
    Li et al., 2005, Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients., J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Patel et al., 2004, Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults., Cancer Chemother. Pharmacol.
    Eliason et al., 2004, Potential for predicting toxicity and response of fluoropyrimidines in patients., Curr Drug Targets
    Tsunoda A et al., 2011, Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study., Ann Oncol
    Ichikawa W et al., 2006, Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen., Clin Cancer Res
    Meulendijks D et al., 2016, Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity., Int J Cancer
    Falvella FS et al., 2015, DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan., Br J Clin Pharmacol
    Amstutz U et al., 2015, Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy., Clin Cancer Res
    Offer SM et al., 2014, microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites., Mol Cancer Ther
    Sebio A et al., 2015, EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer., Pharmacogenomics J
    Kim JG et al., 2009, Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin., Cancer Chemother Pharmacol
    Sclafani et al., 2014, TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial., J. Natl. Cancer Inst.
    Joerger M et al., 2015, Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy., Cancer Chemother Pharmacol
    Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.
    Tol J et al., 2009, BRAF mutation in metastatic colorectal cancer., N Engl J Med
    Jennings BA et al., 2013, Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines., PLoS One
    Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther
    van Huis-Tanja LH et al., 2015, Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients., Pharmacogenet Genomics
    Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
    Yang YC et al., 2017, Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis., Pharmacogenomics J
    Gao J et al., 2013, Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel., Clin Transl Oncol
    Kim SR et al., 2010, Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity., Chemotherapy
    Ruzzo A et al., 2008, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy., Pharmacogenomics J
    Hamzic S et al., 2017, Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity., Clin Pharmacol Ther
    Dong N et al., 2012, Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine., J Cancer Res Clin Oncol
    Loganayagam A et al., 2013, Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity., Br J Cancer
    Caronia D et al., 2011, A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome., Clin Cancer Res
    Ribelles N et al., 2008, A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression., Curr Drug Metab
    Yousef AM et al., 2018, The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer., Cancer Chemother Pharmacol
    Nahid NA et al., 2018, DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer., Cancer Chemother Pharmacol
    Roberto M et al., 2017, Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine., Eur J Clin Pharmacol
    Borro M et al., 2017, Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer., Oncotarget
    Romiti A et al., 2016, The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer., Anticancer Drugs
    Mazzuca F et al., 2016, Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort., Oncotarget
    Chaturvedi P et al., 2015, Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients., Biochem Genet
    Cecchin E et al., 2015, MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin., Pharmacogenomics J
    van Huis-Tanja LH et al., 2013, MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer., Pharmacogenet Genomics
    Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
    Kristensen MH et al., 2010, Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients., J Int Med Res
    Henríquez-Hernández LA et al., 2010, Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy., Cancer Epidemiol
    Boige V et al., 2010, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05., J Clin Oncol
    Gusella M et al., 2009, Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer., Br J Cancer
    Schwab M et al., 2008, Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group., J Clin Oncol
    Sharma R et al., 2008, Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients., Clin Cancer Res
    Capitain O et al., 2008, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer., Pharmacogenomics J
    Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
    Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
    Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
    Gonzalez-Haba E et al., 2010, ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients., Pharmacogenomics
    Zhao J et al., 2014, Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer., Med Oncol
    McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
    Pander J et al., 2015, Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer., PLoS One
  • CAPECITABINE   MIR27A

    Interaction Score: 4.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26804235 25782327 25655103 24401318


    Sources:
    PharmGKB

  • CAPECITABINE   ENOSF1

    Interaction Score: 2.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28347776 27995989 27001118 23263912 20714149 17549067


    Sources:
    PharmGKB

  • CAPECITABINE   CDA

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28347776 24167597 23736036 21325291 18473752


    Sources:
    PharmGKB

  • CAPECITABINE   MIR2054

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CAPECITABINE   CES1P1

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28139840


    Sources:
    PharmGKB

  • CAPECITABINE   ADCY2

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25815774


    Sources:
    PharmGKB

  • CAPECITABINE   MTHFR

    Interaction Score: 1.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29845393 29134491 27995989 27864592 27738344 27557140 26967565 26014925 25331073 24167597 23736036 23407049 23314736 20819423 20638924 20385995 19384296 18299612 18245544 17700593


    Sources:
    PharmGKB

  • CAPECITABINE   UMPS

    Interaction Score: 1.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28347776 20647221 16818689


    Sources:
    PharmGKB

  • CAPECITABINE   SLC22A7

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28347776


    Sources:
    PharmGKB

  • CAPECITABINE   DPYD

    Interaction Score: 0.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16279094 23988873


    Sources:
    NCI CIViC FDA

  • CAPECITABINE   MGAT4A

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26222057


    Sources:
    PharmGKB

  • CAPECITABINE   DLG5

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CAPECITABINE   EXO1

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CAPECITABINE   CDH1

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Lapatinib + Capecitabine
    Indication/Tumor Type breast cancer
    Response Type sensitive

    PMIDs:
    26487584


    Sources:
    JAX-CKB

  • CAPECITABINE   AREG

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25026457


    Sources:
    PharmGKB

  • CAPECITABINE   HLA-G

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CAPECITABINE   REV3L

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CAPECITABINE   TYMP

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24167597


    Sources:
    PharmGKB

  • CAPECITABINE   SELE

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24980946


    Sources:
    PharmGKB

  • CAPECITABINE   TYMS

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Thymidylate synthase inhibitor
    Direct Interaction yes

    PMIDs:
    16926630 15709193 15866500 11752352 15132128 15134221


    Sources:
    ClearityFoundationBiomarkers ClearityFoundationClinicalTrial ChemblInteractions

  • CAPECITABINE   CES1

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28139840


    Sources:
    PharmGKB

  • CAPECITABINE   TYMSOS

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25677447


    Sources:
    PharmGKB

  • CAPECITABINE   ERCC1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25026457


    Sources:
    PharmGKB

  • CAPECITABINE   CYP1A1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22426923


    Sources:
    PharmGKB

  • CAPECITABINE   VEGFA

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25955730 20125120


    Sources:
    PharmGKB

  • CAPECITABINE   ERBB2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    combination therapy Capecitabine + Neratinib
    combination therapy ARRY-380 + Capecitabine + Trastuzumab

    PMIDs:
    20504363 19289619 17192538 26487584 17679724 26920887 26432108 25287822


    Sources:
    JAX-CKB CIViC

  • CAPECITABINE   ABCG2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24338217 20530282


    Sources:
    PharmGKB

  • CAPECITABINE   BRAF

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22180495 19571295


    Sources:
    CIViC

  • CAPECITABINE   CYP19A1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CAPECITABINE   PTGS2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19219602


    Sources:
    PharmGKB

  • CAPECITABINE   PIK3CA

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Lapatinib + Capecitabine
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type decreased response

    PMIDs:
    26920887


    Sources:
    JAX-CKB CIViC

  • CAPECITABINE   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type resistant
    Evidence Type Actionable
    Approval Status Clinical Study

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • CAPECITABINE   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22026922 21142915


    Sources:
    PharmGKB

  • CAPECITABINE   PTEN

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CAPECITABINE   KRAS

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Capecitabine
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • CAPECITABINE   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24957073


    Sources:
    CIViC

  • NCI: CAPECITABINE

    • Version: 14-September-2017

    Alternate Names:
    C1794 NCI drug code

    Drug Info:

    Publications:
    Stepanova et al., 2005, [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]., Vopr Onkol

  • PharmGKB: capecitabine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther
    Hamzic S et al., 2017, Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity., Clin Pharmacol Ther
    Dong N et al., 2012, Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine., J Cancer Res Clin Oncol

  • JAX-CKB: Capecitabine

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Grellety et al., 2016, A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy., Ann. Oncol.
    Bartsch et al., 2007, Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer., J. Clin. Oncol.
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov

  • CIViC: CAPECITABINE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tol J et al., 2009, BRAF mutation in metastatic colorectal cancer., N Engl J Med
    Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.
    Sharon E et al., 2010, Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine., Head Neck Oncol

  • TTD: Capecitabine

    • Version: 2020.06.01

    Alternate Names:
    D00HCQ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1773

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1773

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: CAPECITABINE

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: CAPECITABINE

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Capecitabine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21